Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C-Reference-Cited by-同舟云学术

Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C

Published:2021-11-15 Issue:22 Volume:60 Page:3569-3572
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sato Shunsuke¹,Tsuzura Hironori¹,Kita Yuji¹,Ikeda Yuji¹,Kabemura Daishi¹,Sato Sho¹,Amano Nozomi¹,Yatagai Noboru¹,Murata Ayato¹,Shimada Yuji¹,Genda Takuya¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/22/60_7337-21/_pdf

Reference12 articles.

1. 1. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 67: 1477-1492, 2018.

2. 2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69: 461-511, 2018.

3. 3. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 50: 791-816, 2020.

4. 4. Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients. Hepatol Res 48: 59-68, 2018.

5. 5. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44, 2013.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy;Journal of Clinical Medicine;2022-03-04

2. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial;Clinical Gastroenterology and Hepatology;2021-12